News

 

 

Funding: New Awards

New Awards

Thomas Davis, MD
Member, Cancer Control Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine at Dartmouth Medical School

  • Eisai Medical Research Inc.
    A multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial of E7080 in 131I-refractory differentiated thyroid cancer

Konstantin Dragnev, MD
Member, Cancer Epidemiology and Chemoprevention Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine and of Pharmacology & Toxicology at Dartmouth Medical School

  • CALGB
    A randomized Phase III double-blind trial evaluating selective COX-2 inhibition in COX-2 expressing advanced non-small cell lung cancer

Marc Ernstoff, MD
Member, Immunology and Cancer Immunotherapy Research Program at Norris Cotton Cancer Center, and Professor of Medicine at Dartmouth Medical School

  • AVEO Pharmaceuticals Inc.
    A rollover protocol to allow continued access to tivozanib (AV-951) for subjects enrolled in other tivozanib protocols
  • Prometheus Laboratories Inc.
    Registry protocol 10PLK13 Proleukin® observational registry to evaluate the treatment patterns and clinical response in malignancy

Lionel Lewis, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Professor of Medicine and of Pharmacology & Toxicology at Dartmouth Medical School

  • GlaxoSmithKline Group
    An open-label, Phase Ib continuation study of lapatinib monotherapy or lapatinib in combination with other anticancer treatment in patients with solid tumors

James Rigas, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine at Dartmouth Medical School

  • Bristol Myers Squibb
    Randomized, multicenter, double-blind, Phase 3 trial comparing the efficacy of ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin in subjects with stage IV/recurrent non-small cell lung cancer (NSCLC)

Gary Schwartz, MD
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Associate Professor of Medicine at Dartmouth Medical School

  • Amgen
    A randomized, double-blind, placebo-controlled, multi-center Phase 3 study of denosumab as adjuvant treatment for women with early-stage breast cancer at high risk of recurrence